100290 - Method of the severity of asthma exacerbation evaluation by the Integral indicator

The Integral indicator has been developed on the basis of specialized clinical and functional characteristics of asthma exacerbation (AE) and is used to assess the severity AE. Integral indicator helps us to determine the severity of AE, which further contributes to the correct personalized selection of anti-asthma therapy, which prevents subsequent AE.

The Integral indicator developed by us was used to assess the severity of AE in a clinical study for a comparative analysis of AE among patients with various trigger factors. During the time period of 2024-2025, the study included 82 patients with allergic asthma (AA) aged from 18 to 75, which were treated for relief of AE in a hospital setting. The diagnosis of AA is confirmed by history, screening, clinical, allergological, instrumental examination. Systemic corticosteroids parenterally and nebulizer therapy was carried out in an attempt to stop the AE, the duration of which depended on the objective condition of the patient and the severity of the AE. Based on vital signs (RR, SpO₂, BP, pulse, FEV₁ or PEF, symptoms of RF, etc.), stay in the intensive care unit for monitoring and treatment, then after an objective assessment of the condition, they continued treatment in the allergological department.

The Integral indicator has determined the severity of AE for each patient with AA. The severity of exacerbation AA (N=53) was more against the background of trigger exposure to respiratory viruses, that were detected in their nasal discharge (13,6 ± 2,4; Р<0,05). The severity of exacerbation AA (N=29) of the action of a causally significant allergen was less pronounced (7,2 ± 1,8; Р<0,05).

The Integral indicator is the simple instrument for evaluation of AE severity and can be used in clinical trials for a comparative analysis. The application Integral indicator assessed that the severity of exacerbation AA under trigger exposure to respiratory viruses was more significant, than under the influence of a causally significant allergen.

Supported by Patent ⁽¹⁹⁾RU⁽¹¹⁾2021108617⁽¹³⁾A; 30.03.2021 (https://fips.ru/registers-doc-view/fips_servlet?DB=RUPATAP&DocNumber=2021108617&TypeFile=html/ available 27.02.2026).